The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study.

Guy Heinrich Maria  Jerusalem

Honoraria - Amgen; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche

Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Lilly; Novartis; Pfizer; Puma Biotechnology; Roche

Research Funding - Novartis; Roche

Travel, Accommodations, Expenses - Lilly; Novartis; Pfizer; Roche

Elena  Kovalenko

Consulting or Advisory Role - Roche

Speakers' Bureau - AstraZeneca; Eisai; Roche

Denise A.  Yardley

Consulting or Advisory Role - Genentech/Roche; Genentech/Roche; Novartis; Novartis

Speakers' Bureau - Genentech/Roche; Genentech/Roche; Novartis

Richard H.  De Boer

Honoraria - Amgen; Roche

Consulting or Advisory Role - Amgen; AstraZeneca; Roche

Speakers' Bureau - Novartis

Research Funding - Novartis; Roche

Travel, Accommodations, Expenses - Amgen; Roche

Sara A.  Hurvitz

Research Funding - Amgen (Inst); Bayer (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Dignitana (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Medivation (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Puma Biotechnology (Inst); sanofi (Inst); Seagen (Inst)

Travel, Accommodations, Expenses - Bayer; Lilly; Novartis; OBI Pharma

Bent  Ejlertsen

Research Funding - NanoString Technologies (Inst); Novartis (Inst); Roche (Inst)

Travel, Accommodations, Expenses - AstraZeneca

Sibel  Blau

Employment - University of Washington (I)

Leadership - Northwest Medical Specialties

Stock and Other Ownership Interests  - Northwest Medical Specialties

Consulting or Advisory Role - Bristol-Myers Squibb

Research Funding - Northwest Medical Specialties

Expert Testimony - Northwest Medical Specialties

Travel, Accommodations, Expenses - Northwest Medical Specialties

Other Relationship - All4Cure (I); Northwest Medical Specialties; Quality Cancer Care Alliance

Mustafa  Ozguroglu

Honoraria - Janssen

Consulting or Advisory Role - Astellas Pharma; Janssen

Travel, Accommodations, Expenses - Roche

Laszlo  Landherr

No Relationships to Disclose

Marianne  Ewertz

No Relationships to Disclose

Tanya  Taran

Employment - Novartis

Stock and Other Ownership Interests  - Novartis

Jenna  Fan

Employment - Novartis

Stock and Other Ownership Interests  - Novartis

Florence  Noel-Baron

Employment - Novartis

Anne-Laure  Louveau

Employment - Novartis

Howard A.  Burris

Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); FORMA Therapeutics (Inst); Janssen (Inst); MedImmune (Inst); Mersana (Inst); Novartis (Inst); Roche/Genentech (Inst); TG Therapeutics (Inst)

Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PTC Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); TG Therapeutics (Inst); Valent Technologies (Inst); Verastem (Inst); Vertex (Inst)

Expert Testimony - Novartis